{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:41:16Z","timestamp":1789846876498,"version":"4.0.1"},"reference-count":193,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":3778,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Oncology"},{"name":"Region Europe to the science agency SAN GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1093\/annonc\/mdn796","type":"journal-article","created":{"date-parts":[[2009,5,23]],"date-time":"2009-05-23T00:56:55Z","timestamp":1243040215000},"page":"1303-1317","source":"Crossref","is-referenced-by-count":194,"title":["The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network"],"prefix":"10.1016","volume":"20","author":[{"given":"E.","family":"Terpos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.I.","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Waage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1365-2141.2001.03206.x","article-title":"Diagnosis and management of multiple myeloma","volume":"115","author":"UK Myeloma Forum. British Committee for Standards in Haematology. Haematology BCfSi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdn796_bb0015","series-title":"EUCAN: Cancer Incidence, Mortality and Prevalence in the European Union 1998, version 5.0. IARC CancerBase No 4","author":"Ferlay","year":"1999"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/canjclin.48.1.31","article-title":"Cancer statistics by race and ethnicity","volume":"48","author":"Parker","year":"1998","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdn796_bb0025","series-title":"SEER Cancer Statistics Review, 1975\u20132004","author":"Ries","year":"2007"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0030","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0035","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1634\/theoncologist.12-1-62","article-title":"The use of bisphosphonates in elderly cancer patients","volume":"12","author":"Gridelli","year":"2007","journal-title":"Oncologist"},{"issue":"8 Suppl","key":"10.1093\/annonc\/mdn796_bb0050","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdn796_bb0055","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: pathophysiology and management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0060","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1046\/j.1365-2141.1998.01082.x","article-title":"Bone disease in multiple myeloma","volume":"103","author":"Croucher","year":"1998","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0065","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/leu.2008.159","article-title":"Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma","volume":"22","author":"Jakob","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0070","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","article-title":"Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy","volume":"9","author":"Vogel","year":"2004","journal-title":"Oncologist"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1358\/dot.2004.40.1.799436","article-title":"Bisphosphonate treatment for multiple myeloma","volume":"40","author":"Terpos","year":"2004","journal-title":"Drugs Today (Barc)"},{"issue":"11","key":"10.1093\/annonc\/mdn796_bb0080","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0085","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1365-2141.1999.01194.x","article-title":"Economic impact of using clodronate in the management of patients with multiple myeloma","volume":"104","author":"Bruce","year":"1999","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1093\/annonc\/mdn796_bb0095","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2165\/00003495-200464110-00004","article-title":"Zoledronic acid: a review of its use in patients with advanced cancer","volume":"64","author":"Perry","year":"2004","journal-title":"Drugs"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0100","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","article-title":"American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdn796_bb0105","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0110","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.bbrc.2005.09.146","article-title":"Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease","volume":"338","author":"Heider","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0115","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/sj.leu.2404843","article-title":"The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma","volume":"21","author":"Terpos","year":"2007","journal-title":"Leukemia"},{"issue":"13","key":"10.1093\/annonc\/mdn796_bb0120","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2004.05084.x","article-title":"Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells","volume":"126","author":"Silvestris","year":"2004","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1093\/annonc\/mdn796_bb0130","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0135","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1093\/annonc\/mdn796_bb0140","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0145","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0150","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S8756-3282(99)00275-6","article-title":"Transforming growth factor-beta increases interleukin-6 transcripts in osteoblasts","volume":"26","author":"Franchimont","year":"2000","journal-title":"Bone"},{"issue":"22","key":"10.1093\/annonc\/mdn796_bb0155","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-04-0632","article-title":"Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment","volume":"10","author":"Hayashi","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2141.2003.04374.x","article-title":"Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease","volume":"122","author":"Silvestris","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0165","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.1093\/annonc\/mdn796_bb0170","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","article-title":"Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion","volume":"82","author":"Uchiyama","year":"1993","journal-title":"Blood"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0175","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1365-2141.1999.01193.x","article-title":"Expression of interleukin-1b and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma","volume":"104","author":"Sati","year":"1999","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0180","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/10428194310001593193","article-title":"The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-Kb) and RANK ligand expression","volume":"45","author":"Roux","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"3 Suppl","key":"10.1093\/annonc\/mdn796_bb0185","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cncr.11133","article-title":"Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma","volume":"97","author":"Oyajobi","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdn796_bb0190","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2174\/138945006778559247","article-title":"Proteasome inhibition as a new therapeutic principle in hematological malignancies","volume":"7","author":"Mitsiades","year":"2006","journal-title":"Curr Drug Targets"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0195","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0200","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1046\/j.1365-2141.2003.04712.x","article-title":"New insights into the pathophysiology and management of bone disease in multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0205","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","article-title":"RANK ligand and osteoprotegerin in myeloma bone disease","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn796_bb0210","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1034\/j.1600-065X.2003.00035.x","article-title":"Multiple myeloma biology: lessons from the 5TMM models","volume":"194","author":"Vanderkerken","year":"2003","journal-title":"Immunol Rev"},{"issue":"12 Suppl","key":"10.1093\/annonc\/mdn796_bb0215","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"issue":"7679","key":"10.1093\/annonc\/mdn796_bb0220","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0140-6736(70)92070-2","article-title":"Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout)","volume":"2","author":"Russell","year":"1970","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0225","first-page":"27","article-title":"Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix","volume":"1","author":"Boonekamp","year":"1986","journal-title":"Bone Miner"},{"issue":"7","key":"10.1093\/annonc\/mdn796_bb0230","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11626-999-0112-7","article-title":"Relationship between bisphosphonate concentration and osteoclast activity and viability","volume":"35","author":"Rowe","year":"1999","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0235","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":"Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2032-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro","volume":"12","author":"Frith","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1093\/annonc\/mdn796_bb0240","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0245","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0026-895X(25)09541-0","article-title":"Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages","volume":"50","author":"Selander","year":"1996","journal-title":"Mol Pharmacol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdn796_bb0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0255","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1093\/annonc\/mdn796_bb0260","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0265","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1999.0224","article-title":"Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase\/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo","volume":"255","author":"van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0270","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0275","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1359\/jbmr.060118","article-title":"Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases","volume":"21","author":"Dunford","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1093\/annonc\/mdn796_bb0280","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","article-title":"Effect of daily etidronate on the osteolysis of multiple myeloma","volume":"9","author":"Belch","year":"1991","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdn796_bb0285","first-page":"449","article-title":"Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myelome (GERM)","volume":"2","author":"Daragon","year":"1993","journal-title":"Eur J Med"},{"issue":"8827","key":"10.1093\/annonc\/mdn796_bb0290","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0295","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2141.1994.tb06730.x","article-title":"Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"87","author":"Laakso","year":"1994","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0300","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0305","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group","volume":"101","author":"Brincker","year":"1998","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1093\/annonc\/mdn796_bb0310","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0315","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0320","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdn796_bb0325","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0330","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"issue":"8","key":"10.1093\/annonc\/mdn796_bb0335","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn796_bb0340","doi-asserted-by":"crossref","first-page":"118","DOI":"10.6004\/jnccn.2007.0014","article-title":"Multiple myeloma guidelines","volume":"5","author":"Anderson","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"10.1093\/annonc\/mdn796_bb0345","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdn796_bb0350","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdn796_bb0355","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/annonc\/mdi818","article-title":"ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of multiple myeloma","volume":"16","author":"Harrouseau","year":"2005","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0360","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4065\/82.4.516","article-title":"Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement","volume":"82","author":"Durie","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdn796_bb0365","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0370","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0375","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jpainsymman.2007.01.001","article-title":"Managing metastatic bone pain: the role of bisphosphonates","volume":"33","author":"Gralow","year":"2007","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0380","article-title":"Bisphosphonates for the relief of pain secondary to bone metastases","author":"Wong","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0385","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1600-0609.2000.065005331.x","article-title":"Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma","volume":"65","author":"Terpos","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdn796_bb0390","unstructured":"WHO's pain relief ladderhttp:\/\/www.who.int\/cancer\/palliative\/painladder\/en\/ (19 May 2009, data last accessed)"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0395","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3174\/ajnr.A0918","article-title":"Vertebroplasty in multiple myeloma: outcomes in a large patient series","volume":"29","author":"McDonald","year":"2008","journal-title":"AJNR Am J Neuroradiol"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0400","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2002.09.097","article-title":"Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma","volume":"20","author":"Dudeney","year":"2002","journal-title":"J Clin Oncol"},{"issue":"415 Suppl","key":"10.1093\/annonc\/mdn796_bb0405","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1097\/01.blo.0000093841.72468.a8","article-title":"Vertebroplasty and kyphoplasty for osteolytic vertebral collapse","author":"Lieberman","year":"2003","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0410","first-page":"S26","article-title":"Early phase in the development of a bone metastases quality of life module","volume":"19","author":"Chow","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0415","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.4161\/cbt.5.9.3307","article-title":"Bone complications in multiple myeloma","volume":"5","author":"Berenson","year":"2006","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0420","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S8756-3282(02)00841-4","article-title":"The absolute bioavailability of clodronate from two different oral doses","volume":"31","author":"Villikka","year":"2002","journal-title":"Bone"},{"issue":"8","key":"10.1093\/annonc\/mdn796_bb0425","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1093\/annonc\/mdn796_bb0430","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1185\/030079906X154042","article-title":"Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate","volume":"22","author":"Gold","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"5 Suppl 10","key":"10.1093\/annonc\/mdn796_bb0435","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1053\/j.seminoncol.2004.07.027","article-title":"Patient management issues in metastatic bone disease","volume":"31","author":"Cameron","year":"2004","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0440","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.1995.13.9.2427","article-title":"Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study","volume":"13","author":"Robertson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn796_bb0445","article-title":"Poor persistancy with oral bisphosphonates in cancer patients with bone metastasis","volume":"31","author":"G\u00f6l","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"18 Suppl","key":"10.1093\/annonc\/mdn796_bb0450","article-title":"Higher persistency with i.v. bisphosphonates in patients with bone metastasis","volume":"24","author":"Mangiapane","year":"2006","journal-title":"ASCO Meeting Abstracts. J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0455","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00520-004-0628-z","article-title":"Bisphosphonate infusions: patient preference, safety and clinic use","volume":"12","author":"Chern","year":"2004","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdn796_bb0460","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0465","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn796_bb0470","article-title":"Oral clodronate maintains bone mass in women with primary breast cancer","volume":"23","author":"McCloskey","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0475","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14737140.5.2.221","article-title":"Clodronate in the prevention and treatment of skeletal metastasis","volume":"5","author":"Gulley","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0480","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1592\/phco.26.5.655","article-title":"Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy","volume":"26","author":"Guay","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0485","first-page":"478","article-title":"Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience)","volume":"59","author":"Kraj","year":"2002","journal-title":"Acta Pol Pharm"},{"issue":"6 Suppl 1","key":"10.1093\/annonc\/mdn796_bb0490","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/00000421-200212001-00005","article-title":"Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials","volume":"25","author":"Coleman","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdn796_bb0495","article-title":"Summary of product characteristics (SmPC) clodronate","year":"2006","journal-title":"Bonefos\u00ae. Swissmedic (50957, 50958)"},{"issue":"10","key":"10.1093\/annonc\/mdn796_bb0500","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdn796_bb0505","unstructured":"SmPC clodronatehttp:\/\/www.compendium.ch\/MonographieTxt.aspx?lang=de&;MonType=fi"},{"key":"10.1093\/annonc\/mdn796_bb0510","unstructured":"SmPC zoledronic acidhttp:\/\/www.compendium.ch\/MonographieTxt.aspx?lang=de&;MonType=fi"},{"issue":"11","key":"10.1093\/annonc\/mdn796_bb0515","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.533.533","article-title":"Randomised study on prophylactic pamidronate 30 mg versus 90 mg in multiple myeloma","volume":"110","author":"Gimsing","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0520","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/sj.thj.6200311","article-title":"Perspective study on pamidronate in stage I multiple myeloma","volume":"4","author":"Caparrotti","year":"2003","journal-title":"Hematol J"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0525","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3109\/10428190309178778","article-title":"Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial","volume":"44","author":"Musto","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0530","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2401770","article-title":"Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines","volume":"14","author":"Tassone","year":"2000","journal-title":"Leukemia"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0535","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1349-7006.2004.tb03202.x","article-title":"p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid","volume":"95","author":"Kuroda","year":"2004","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0540","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/10245330500094714","article-title":"Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment","volume":"10","author":"Corso","year":"2005","journal-title":"Hematology"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0545","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.leu.2400892","article-title":"In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates","volume":"12","author":"Aparicio","year":"1998","journal-title":"Leukemia"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0550","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","article-title":"Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity","volume":"98","author":"Shipman","year":"1997","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0555","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.leukres.2006.07.018","article-title":"Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma","volume":"31","author":"Baulch-Brown","year":"2007","journal-title":"Leuk Res"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0560","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","article-title":"Gammadelta T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0565","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0570","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","author":"Yaccoby","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0575","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0580","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1365-2141.1998.00976.x","article-title":"Anti-myeloma activity of pamidronate in vivo","volume":"103","author":"Dhodapkar","year":"1998","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0585","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/10428190290017123","article-title":"Anti-tumor activity of pamidronate in human multiple myeloma","volume":"43","author":"Kondo","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0590","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2141.2000.02310.x","article-title":"The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma","volume":"111","author":"Shipman","year":"2000","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0595","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","article-title":"Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease","volume":"93","author":"Dallas","year":"1999","journal-title":"Blood"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0600","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0301-472X(01)00618-X","article-title":"Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma","volume":"29","author":"Cruz","year":"2001","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0605","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0610","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2520.x","article-title":"First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma","volume":"76","author":"Tosi","year":"2006","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0615","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ijc.11247","article-title":"Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma","volume":"106","author":"Terpos","year":"2003","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0620","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1600-0609.2003.02823.x","article-title":"Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma","volume":"70","author":"Terpos","year":"2003","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0625","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect","volume":"118","author":"Martin","year":"2002","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1093\/annonc\/mdn796_bb0630","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/sj.leu.2403890","article-title":"The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory\/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL\/osteoprotegerin ratio","volume":"19","author":"Terpos","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0635","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","article-title":"Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease","volume":"4","author":"Dunstan","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0640","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM198002073020602","article-title":"Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma","volume":"302","author":"Siris","year":"1980","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0645","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)40597-0","article-title":"Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study","volume":"141","author":"Smith","year":"1989","journal-title":"J Urol"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0650","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF01622190","article-title":"Pamidronate: an unrecognized problem in gastrointestinal tolerability","volume":"4","author":"Lufkin","year":"1994","journal-title":"Osteoporos Int"},{"issue":"14","key":"10.1093\/annonc\/mdn796_bb0655","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn796_bb0660","doi-asserted-by":"crossref","unstructured":"F Alves JD Prado AC Rocha. Clinical features and management of jaw osteonecrosis in patients receiving bisphosphonate therapyASH Annual Meeting Abstracts. Blood 2007; 110 (11 Suppl\/part 2): 267b (Abstr 4775)","DOI":"10.1182\/blood.V110.11.4775.4775"},{"issue":"19","key":"10.1093\/annonc\/mdn796_bb0665","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0670","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0889-8588(05)70232-X","article-title":"Complementary and alternative therapies for advanced prostate cancer","volume":"15","author":"Smith","year":"2001","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0675","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0680","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00130404-200207000-00012","article-title":"Electrolyte abnormalities with zoledronic acid therapy","volume":"8","author":"Sorscher","year":"2002","journal-title":"Cancer J"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0685","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0885-3924(00)00133-0","article-title":"An unusual coma after therapy for bone pain","volume":"19","author":"Mercadante","year":"2000","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0690","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0936-6555(98)80045-9","article-title":"Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia","volume":"10","author":"Sims","year":"1998","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"7435","key":"10.1093\/annonc\/mdn796_bb0695","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bmj.328.7435.335","article-title":"Severe hypocalcaemia after being given intravenous bisphosphonate","volume":"328","author":"Peter","year":"2004","journal-title":"BMJ"},{"issue":"7 Suppl 1","key":"10.1093\/annonc\/mdn796_bb0700","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.3816\/CBC.2007.s.002","article-title":"Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer","author":"Lipton","year":"2007","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0705","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"issue":"17","key":"10.1093\/annonc\/mdn796_bb0710","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1093\/annonc\/mdn796_bb0715","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"16","key":"10.1093\/annonc\/mdn796_bb0720","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn796_bb0725","series-title":"The Role of Phosphonates in Living Systems","first-page":"55","article-title":"Chemical, biochemical, and medical properties of the diphosphonates","author":"Francis","year":"1983"},{"issue":"12","key":"10.1093\/annonc\/mdn796_bb0730","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00520-004-0655-9","article-title":"Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy","volume":"12","author":"Pecherstorfer","year":"2004","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdn796_bb0735","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/0091270007301801","article-title":"Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function","volume":"47","author":"Bergner","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"8322","key":"10.1093\/annonc\/mdn796_bb0740","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(83)91465-4","article-title":"Renal failure associated with intravenous diphosphonates","volume":"1","author":"Bounameaux","year":"1983","journal-title":"Lancet"},{"issue":"9 Suppl 4","key":"10.1093\/annonc\/mdn796_bb0745","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","author":"Conte","year":"2004","journal-title":"Oncologist"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0750","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/ajkd.2002.32797","article-title":"Nephrotic syndrome after treatment with pamidronate","volume":"39","author":"Markowitz","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0755","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08998280.2007.11928298","article-title":"Reversibility of pamidronate-associated glomerulosclerosis","volume":"20","author":"Shreedhara","year":"2007","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0760","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates\u2014histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen","year":"2006","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0765","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"34","key":"10.1093\/annonc\/mdn796_bb0770","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0775","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"issue":"12","key":"10.1093\/annonc\/mdn796_bb0780","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.14219\/jada.archive.2005.0110","article-title":"Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition","volume":"136","author":"Melo","year":"2005","journal-title":"J Am Dent Assoc"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0785","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"issue":"7","key":"10.1093\/annonc\/mdn796_bb0790","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0795","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0800","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0805","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn796_bb0810","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/asheducation-2006.1.356","article-title":"Bisphosphonate complications including osteonecrosis of the jaw","author":"Mehrotra","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0815","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0609.2007.00872.x","article-title":"Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma","volume":"79","author":"Montazeri","year":"2007","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0820","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.tripleo.2006.10.010","article-title":"Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases","volume":"103","author":"Brooks","year":"2007","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"10","key":"10.1093\/annonc\/mdn796_bb0825","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00198-007-0384-2","article-title":"Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome","volume":"18","author":"Yarom","year":"2007","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0830","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"7","key":"10.1093\/annonc\/mdn796_bb0835","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0840","first-page":"176","article-title":"[Osteonecrosis of the jaw in the course of multiple myeloma treatment and bisphosphonate administration]","volume":"52","author":"Adam","year":"2006","journal-title":"Vnitr Lek"},{"issue":"10","key":"10.1093\/annonc\/mdn796_bb0845","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"issue":"36","key":"10.1093\/annonc\/mdn796_bb0850","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","article-title":"Natural history of osteonecrosis of the jaw in patients with multiple myeloma","volume":"26","author":"Badros","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn796_bb0855","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdn796_bb0860","first-page":"2156","article-title":"Antibiotic prophylaxis before dental procedures may reduce","volume":"49","author":"Montefusco","year":"2008","journal-title":"the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdn796_bb0865","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1093\/annonc\/mdn796_bb0870","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdn796_bb0875","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0880","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02390835","article-title":"Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment","volume":"68","author":"Terpos","year":"2001","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0885","first-page":"567","article-title":"Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma","volume":"89","author":"Abildgaard","year":"2004","journal-title":"Haematologica"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0890","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.blre.2004.06.001","article-title":"The role of markers of bone remodeling in multiple myeloma","volume":"19","author":"Terpos","year":"2005","journal-title":"Blood Rev"},{"issue":"11","key":"10.1093\/annonc\/mdn796_bb0895","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.ejca.2005.11.034","article-title":"Bone markers in multiple myeloma","volume":"42","author":"Heider","year":"2006","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0900","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3816\/CLM.2007.n.011","article-title":"Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma","volume":"7","author":"Lipton","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0905","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0609.2002.00505.x","article-title":"Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma","volume":"69","author":"Jakob","year":"2002","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1093\/annonc\/mdn796_bb0910","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.thj.6200564","article-title":"Bone remodelation markers are useful in the management of monoclonal gammopathies","volume":"5","author":"Hernandez","year":"2004","journal-title":"Hematol J"},{"issue":"8","key":"10.1093\/annonc\/mdn796_bb0915","first-page":"3047","article-title":"Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography","volume":"9","author":"Jakob","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0920","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ajh.20961","article-title":"Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients","volume":"82","author":"Zangari","year":"2007","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1093\/annonc\/mdn796_bb0925","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1093\/annonc\/mdn796_bb0930","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0935","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00256-006-0184-3","article-title":"PET\/CT and MR imaging in myeloma","volume":"36","author":"Mulligan","year":"2007","journal-title":"Skeletal Radiol"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0940","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0009-9260(67)80010-2","article-title":"The radiological demonstration of osseous metastases. Experimental observations","volume":"18","author":"Edelstyn","year":"1967","journal-title":"Clin Radiol"},{"issue":"4","key":"10.1093\/annonc\/mdn796_bb0945","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2214\/ajr.184.4.01841199","article-title":"Value of FDG PET in the assessment of patients with multiple myeloma","volume":"184","author":"Bredella","year":"2005","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1093\/annonc\/mdn796_bb0950","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdn796_bb0955","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1179\/joc.2005.17.5.555","article-title":"The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers","volume":"17","author":"Fulfaro","year":"2005","journal-title":"J Chemother"},{"key":"10.1093\/annonc\/mdn796_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2007.10.025","article-title":"Whole-body MRI of multiple myeloma: comparison of different MRI sequences in assessment of different growth patterns","author":"Weininger","year":"2009","journal-title":"Eur J Radiol"},{"issue":"11","key":"10.1093\/annonc\/mdn796_bb0965","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","article-title":"The role of anatomic and functional staging in myeloma: description of Durie\/Salmon plus staging system","volume":"42","author":"Durie","year":"2006","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdn796_bb0970","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejrad.2005.01.017","article-title":"Role of MRI for the diagnosis and prognosis of multiple myeloma","volume":"55","author":"Baur-Melnyk","year":"2005","journal-title":"Eur J Radiol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419409502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419409502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/20\/8\/1303\/342080\/mdn796.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T17:30:13Z","timestamp":1739122213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419409502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":193,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0923753419409502"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn796","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}